Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PACB

Pacific Biosciences of California, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for PACB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.41

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a medical device company. Figures from SEC EDGAR; updated 2026-10-21 14:31 UTC.

What Pacific Biosciences of California, Inc. does

The company designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to study genomes, transcriptomes, and epigenomes. Its products, including HiFi long-read sequencing technology, serve applications in human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging areas.

Summarized from Pacific Biosciences of California, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.41

Revenue, margins & earnings

FY2021: net loss $181M on revenue $131M$131MFY2021FY2022: net loss $314M on revenue $128M$128MFY2022FY2023: net loss $307M on revenue $201M$201MFY2023FY2024: net loss $310M on revenue $154M$154MFY2024FY2025: net loss $546M on revenue $160M$160MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-08
  • 2026-10-08See RemarksStock Option (right to buy)Option exercise-500,000—
  • 2026-10-08See RemarksSale-661,815$2.06M
  • 2026-10-08See RemarksOption exercise500,000$590.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Pacific Biosciences of California, Inc. do?

The company designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to study genomes, transcriptomes, and epigenomes.

When did PACB last file with the SEC?

Pacific Biosciences of California, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 14:31 UTC. This page is also available as JSON at /api/data?ticker=PACB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PACB and 5,000+ tickers.

Create a free account — keep PACB
For your agent
GET /api/data?ticker=PACB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt